A detailed history of Invesco Ltd. transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 11,641 shares of RAPT stock, worth $9,778. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,641
Previous 12,130 4.03%
Holding current value
$9,778
Previous $36,000 36.11%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$1.76 - $3.75 $860 - $1,833
-489 Reduced 4.03%
11,641 $23,000
Q2 2024

Aug 13, 2024

SELL
$2.89 - $9.38 $4,034 - $13,094
-1,396 Reduced 10.32%
12,130 $36,000
Q1 2024

May 14, 2024

SELL
$6.87 - $26.45 $354,711 - $1.37 Million
-51,632 Reduced 79.24%
13,526 $121,000
Q4 2023

Feb 12, 2024

BUY
$11.28 - $25.46 $450,128 - $1.02 Million
39,905 Added 158.02%
65,158 $1.62 Million
Q3 2023

Nov 13, 2023

BUY
$16.34 - $24.66 $184,919 - $279,077
11,317 Added 81.21%
25,253 $419,000
Q2 2023

Aug 11, 2023

SELL
$16.06 - $21.61 $19,079 - $25,672
-1,188 Reduced 7.86%
13,936 $260,000
Q1 2023

May 12, 2023

BUY
$17.19 - $30.8 $259,981 - $465,819
15,124 New
15,124 $277,000
Q3 2022

Nov 14, 2022

BUY
$17.96 - $30.46 $2.78 Million - $4.72 Million
154,934 New
154,934 $3.73 Million
Q2 2022

Aug 15, 2022

SELL
$10.26 - $23.59 $97,705 - $224,647
-9,523 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$17.02 - $40.22 $902 - $2,131
53 Added 0.56%
9,523 $209,000
Q4 2021

Feb 14, 2022

SELL
$29.5 - $39.5 $1.44 Million - $1.93 Million
-48,834 Reduced 83.76%
9,470 $348,000
Q3 2021

Nov 15, 2021

BUY
$29.86 - $39.47 $1.51 Million - $1.99 Million
50,520 Added 649.02%
58,304 $1.81 Million
Q2 2021

Aug 17, 2021

BUY
$17.99 - $40.02 $140,034 - $311,515
7,784 New
7,784 $247,000

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $24.9M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.